Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company miRagen Therapeutics Inc.
DescriptionModified short nucleic acid sequence targeting microRNA-92
Molecular Target MicroRNA-92a (miR-92a)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: microRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationPeripheral vascular disease (PVD)
Indication DetailsTreat peripheral arterial disease (PAD)
Regulatory Designation
Partnert2cure GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today